PRN Pharmacal acquires VPL; Bimeda and Ceva announce agreement on equine
Two companies in the veterinary industry recently announced acquisitions in order to expand their reach in the veterinary product arena. PRN Pharmacal plans to acquire VPL's animal health business, and Bimeda has acquired Ceva's equine product portfolio.
PRN Pharmacal to buy VPL
Pegasus Laboratories Inc., doing business as PRN Pharmacal, announced the acquisition of Veterinary Products Laboratories’ (VPL’s) animal health assets. The acquisition will strengthen PRN Pharmacal’s product portfolio while expanding its reach into a number of therapeutic categories not previously serviced by the company, a PRN release states.
“The addition of the VPL product lines to our pharmaceutical and nutritional portfolio is a natural fit as we continue to expand and grow,” says Donna Logan, Pegasus’ general manager. “At PRN our goal is to serve veterinary niche markets and the underserved needs of the animal health community. With this acquisition we will be able to do this better than ever.”
VPL is a division of Central Life Sciences focused on inflammation support, surgical suite supplies and environmental parasite control. PRN’s purchase of its assets will include the following:
> Duralactin (milk protein)
> Zentrol (calming supplement)
> The Vet-Kem family of flea and tick control products
> Monomend, Polymend and Chromend absorbable sutures
> NY-STA and PRO-STA nonabsorbable sutures
> Tissumend II absorbable tissue adhesive
> Optima 365 fatty acid supplement.
It will also include a continued partnership with Becton, Dickinson & Co. (BD) to represent its surgical and medical device brands in the veterinary market.
Bimeda acquires Ceva equine
Bimeda Inc., an international developer, manufacturer and marketer of veterinary pharmaceuticals and animal health products, has acquired the marketing rights to Ceva Animal Health’s portfolio of equine products in the United States, according to a recent release from Bimeda.
This agreement with Ceva—a veterinary health company targeting companion animals, poultry and swine—will strategically expand Bimeda into the equine market, the release states.
Ceva’s U.S. portfolio includes Tildren (tiludronate disodium), Altresyn (altrenogest), ConfidenceEQ (a pheromone analog) and PentosanEQ (pentosan polysulfate). Bimeda also acquired the marketing rights for Tildren in Canada.
“This agreement is a key milestone in Bimeda’s strategic expansion into the Equine market,” says Alan Kelly, Director of Commercial Development for Bimeda North America, in the release. “With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America.”